SARS-CoV-2/COVID-19 Evolving Reality, Global Response, Knowledge Gaps and Opportunities /
Approximately 3 billion people around the world have gone into some form of social separation to mitigate the current SARS-CoV-2 pandemic. The uncontrolled influx of patients in need of emergency care has rapidly brought several national health systems to near-collapse with deadly consequences to th...
Saved in:
| Main Authors: | |
|---|---|
| Format: | Article |
| Published: |
2020
|
| Series: | SHOCK
54 No. 4 |
| doi: | 10.1097/SHK.0000000000001565 |
| mtmt: | 31323001 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/19916 |
| Summary: | Approximately 3 billion people around the world have gone into some form of social separation to mitigate the current SARS-CoV-2 pandemic. The uncontrolled influx of patients in need of emergency care has rapidly brought several national health systems to near-collapse with deadly consequences to those afflicted by COVID-19 and other critical diseases associated with COVID-19. Solid scientific evidence regarding SARS-CoV-2/COVID-19 remains scarce; there is an urgent need to expand our understanding of the SARS-CoV-2 pathophysiology to facilitate precise and targeted treatments. The capacity for rapid information dissemination has emerged as a double-edged sword; the existing gap of high-quality data is frequently filled by anecdotal reports, contradictory statements and misinformation. This review addresses several important aspects unique to the SARS-CoV-2/COVID-19 pandemic highlighting the most relevant knowledge gaps and existing windows-of-opportunity. Specifically, focus is given to SARS-CoV-2 immunopathogenesis in the context of experimental therapies and pre-clinical evidence and their applicability in supporting efficacious clinical trial planning. The review discusses the existing challenges of SARS-CoV-2 diagnostics and the potential application of translational technology for epidemiological predictions, patient monitoring and treatment decision-making in COVID-19. Furthermore, solutions for enhancing international strategies in translational research, cooperative networks and regulatory partnerships are contemplated. Address reprint requests to Marc Maegele, Department of Trauma and Orthopaedic Surgery, Cologne-Merheim Medical Center (CMMC), Institute for Research in Operative Medicine (IFOM), University of Witten/Herdecke, Cologne-Merheim Campus, Cologne, Germany. E-mail: Marc.Maegele@t-online.de; Marcin F. Osuchowski, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Donaueschingenstrasse 13, 1200 Vienna, Austria. E-mail: marcin.osuchowski@trauma.lbg.ac.at. Received 22 April, 2020 Revised 29 April, 2020 Accepted 5 May, 2020 Osuchowski M: no conflict of interest Aletti F: no conflict of interest Cavaillon J-M: no conflict of interest Flohe SB: no conflict of interest Giamarellos-Bourboulis EJ: honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc, InflaRx GmbH, and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). Huber-Lang M: no conflict of interest Relja B: no conflict of interest Skirecki T: no conflict of interest Szabó A: no conflict of interest Maegele M: no conflict of interest © 2020 by the Shock Society |
|---|---|
| Physical Description: | 416-437 |
| ISSN: | 1073-2322 |